Family members of a woman who suffered jawbone decay allegedly caused by the bone drug Zometa may try their suit against Novartis Pharmaceuticals Corp., a federal court in Rhode Island said (Esposito v. Novartis Pharms. Corp., 2015 BL 304455, D.R.I., 1:09-cv-00563-S-LDA, 9/18/15).
Roselyn Esposito’s daughter and husband alleged she developed Zometa-related osteonecrosis of the jaw following dental work, the U.S. District Court for the District of Rhode Island said.
She was given a diagnosis of Stage III bisphosphonate-related osteonecrosis of the jaw in 2008, according to Chief Judge William E. Smith’s opinion. Esposito died in November 2008 ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.